Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACAT2 | Q9BWD1 | 1/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.34 |
| ▸ | CDK9 | P50750 | 2/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | HTR6 | P50406 | 2/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17757986 | 0.97 | ACAT2 (0.38) | ACAT2CCNT1CDK9BRD4MAOB | |
| SCHEMBL17758029 | 0.86 | ACAT2 (0.45) | ACAT2CCNT1CDK9MAOBHTR6 | |
| SCHEMBL17757745 | 0.85 | ACAT2 (0.43) | ACAT2CCNT1CDK9MAOBHTR6 | |
| SCHEMBL17757323 | 0.85 | TAAR1 (0.46) | ACAT2CCNT1CDK9BRD4MAOB | |
| SCHEMBL17758022 | 0.84 | ACAT2 (0.41) | ACAT2CCNT1CDK9BRD4MAOB | |
| SCHEMBL17757954 | 0.83 | ACAT2 (0.37) | ACAT2CCNT1MAOBHTR6 | |
| SCHEMBL17757773 | 0.82 | ACAT2 (0.45) | ACAT2CCNT1CDK9MAOBHTR6 | |
| SCHEMBL17757783 | 0.82 | TAAR1 (0.45) | ACAT2CCNT1CDK9BRD4MAOB | |
| SCHEMBL17757776 | 0.82 | ACAT2 (0.48) | ACAT2CCNT1CDK9MAOBHTR6 | |
| SCHEMBL17757310 | 0.82 | ACAT2 (0.43) | ACAT2CCNT1CDK9MAOBHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647687-B2 | Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death | HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2020-05-12 | — | — | US | disclosed |
| WO-2016075137-A1 | SPIROPYRAZINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2016-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647687-B2 | Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death | AIFM2, BAD, AIFM1 | ACAT2 1935/4885CCNT1 4252/4885CDK9 3993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.